Top entities: BioSyent, René Goehrum, TSX Venture Exchange.

What category does this event fall under?

Business — classified as earnings release.

What is the sentiment of coverage?

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 13, 2026. Coverage continues to evolve.

Business earnings release

BioSyent Schedules Q2 2026 Earnings Release

Q: When did this event occur?

First reported Aug 13, 2026; last updated Aug 13, 2026.

Q: What is the market impact?

General. The announcement is a routine scheduling notice and is unlikely to have a significant impact on BioSyent's stock price or the broader market.

Analysis based on 9 articles · First reported Aug 13, 2026 · Last updated Aug 13, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The announcement is a routine scheduling notice and is unlikely to have a significant impact on BioSyent's stock price or the broader market. Investors may anticipate the upcoming earnings report, but no financial results have been disclosed yet.

Pharmaceuticals

Event Summary

BioSyent Inc., a specialty healthcare products company listed on the TSX Venture Exchange under the symbol RX, announced that it will report its consolidated financial results for the three and six months ended June 30, 2026, on Thursday, August 13, 2026, after market hours. The company also stated that a presentation on the second quarter and first half 2026 results by René Goehrum, President and CEO, will be available on the company's website on the date of release. As of the date of the press release, BioSyent has 11,312,635 common shares outstanding. The announcement is a routine scheduling notice for the company's upcoming earnings release.

Key Actions

100 BioSyent scheduled earnings release

Entities Involved

stock

BioSyent

BioSyent is the company announcing its earnings release schedule. The event is a routine corporate communication with no immediate financial impact.

Importance 100.0 Sentiment 0.0

per

René Goehrum

René Goehrum, as President and CEO, will present the company's results. His role is to communicate the financial performance to stakeholders.

Importance 20.0 Sentiment 0.0

exch

TSX Venture Exchange

TSX Venture Exchange is the listing exchange for BioSyent. The event is a routine disclosure requirement for listed companies.

Importance 10.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard